Brevilin A reverses colitis of inflammatory bowel disease via modulation of TNF-α signaling and microbiome dysregulation
Liming Chen, Chaotao Tang, Diping Hu, Shujiao Yu, Peng Liao · 2025
Read Brevilin A reverses colitis of inflammatory bowel disease via modulation of TNF-α signaling and microbiome dysregulation by Liming Chen, Chaotao Tang, Diping Hu, Shujiao Yu, Peng Liao (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12765297.txt.
Description
Liming Chen and co-authors test a plant compound, brevilin A, against gut inflammation in mice. Colitis, the inflamed colon seen in inflammatory bowel disease, was triggered with a chemical in the animals' water. Doses of the compound then eased the disease, and the team traced how.
Brevilin A reshaped the gut's microbe mix, favoring helpful Lactobacillus while thinning harmful kinds. It also shifted the chemicals those microbes make and turned down a key inflammation signal, TNF-alpha; forcing that signal back on erased the benefit. Stool transplants from treated mice passed part of the gain to untreated ones, proving the microbes carry part of the effect. The authors pitch the compound as a candidate drug worth clinical study.
Catalog record
| CREATOR | Liming Chen, Chaotao Tang, Diping Hu, Shujiao Yu, Peng Liao |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 42 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |